Relmada Therapeutics (RLMD) FCF Margin (2012 - 2013)
Relmada Therapeutics' (RLMD) quarterly FCF Margin came in at 493.19% in Q4 2013, down 56285.0% year-on-year from N/an in Q4 2012, and down 293.28% on a QoQ basis from 125.4% in Q1 2013.
Relmada Therapeutics (RLMD) FCF Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of FCF Margin data on file, last reported at 493.19% in Q4 2013.
- On a quarterly basis, FCF Margin fell 56285.0% year-over-year to 493.19% in Q4 2013; TTM through Nov 2013 was 249.81%, a N/A change from a year earlier, with the FY2013 full-year figure at 196.12%, down 10086.0% from the prior year.
- FCF Margin for Q4 2013 stood at 493.19%, down from 125.4% in the prior quarter.
- Over the last five years, FCF Margin for RLMD reached as high as 69.66% in Q4 2012 and fell as low as 496.5% in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -493.19% |
| Feb 28, 2013 | -125.40% |
| Nov 30, 2012 | 69.66% |
| Aug 31, 2012 | -220.73% |
| May 31, 2012 | -496.50% |